Ocumension Therapeutics (HKG:1477)
Hong Kong
· Delayed Price · Currency is HKD 7.50
+0.05 (0.67%)
Apr 29, 2026, 4:08 PM HKT
Ocumension Therapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 804.35 | 417.31 | 246.37 | 158.96 | 56.15 | Upgrade
|
| Revenue Growth (YoY) | 92.75% | 69.38% | 54.99% | 183.11% | 328.73% | Upgrade
|
| Cost of Revenue | 443.43 | 192.24 | 102 | 56.04 | 19.21 | Upgrade
|
| Gross Profit | 360.92 | 225.07 | 144.37 | 102.92 | 36.94 | Upgrade
|
| Selling, General & Admin | 445.39 | 416.91 | 422.4 | 373.79 | 253.81 | Upgrade
|
| Research & Development | 75.08 | 113.94 | 123.77 | 184.31 | 169.06 | Upgrade
|
| Operating Expenses | 521.13 | 531.5 | 546.51 | 558.78 | 422.86 | Upgrade
|
| Operating Income | -160.2 | -306.43 | -402.15 | -455.86 | -385.93 | Upgrade
|
| Interest Expense | -2.45 | -2.16 | -1.33 | -1.79 | -0.57 | Upgrade
|
| Interest & Investment Income | 6.4 | 22.22 | 21.92 | 28.22 | 26.89 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -13.33 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.9 | 1.92 | 1.1 | 22.42 | -13.37 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.58 | 16.91 | -3.36 | 7.31 | 0.54 | Upgrade
|
| EBT Excluding Unusual Items | -161.74 | -267.55 | -383.81 | -399.71 | -385.77 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.27 | 0.29 | 1.16 | 1.25 | 99.84 | Upgrade
|
| Asset Writedown | - | - | 3.18 | -3.18 | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.6 | 25.94 | Upgrade
|
| Pretax Income | -158.47 | -267.26 | -379.48 | -402.23 | -259.99 | Upgrade
|
| Income Tax Expense | 0.35 | 1.02 | 0.31 | 0.41 | - | Upgrade
|
| Earnings From Continuing Operations | -158.82 | -268.27 | -379.79 | -402.64 | -259.99 | Upgrade
|
| Net Income | -158.82 | -268.27 | -379.79 | -402.64 | -259.99 | Upgrade
|
| Net Income to Common | -158.82 | -268.27 | -379.79 | -402.64 | -259.99 | Upgrade
|
| Shares Outstanding (Basic) | 794 | 684 | 649 | 633 | 607 | Upgrade
|
| Shares Outstanding (Diluted) | 794 | 684 | 649 | 633 | 607 | Upgrade
|
| Shares Change (YoY) | 16.13% | 5.33% | 2.63% | 4.18% | 100.81% | Upgrade
|
| EPS (Basic) | -0.20 | -0.39 | -0.59 | -0.64 | -0.43 | Upgrade
|
| EPS (Diluted) | -0.20 | -0.39 | -0.59 | -0.64 | -0.43 | Upgrade
|
| Free Cash Flow | - | -225.92 | -258.84 | -316.47 | -392.22 | Upgrade
|
| Free Cash Flow Per Share | - | -0.33 | -0.40 | -0.50 | -0.65 | Upgrade
|
| Gross Margin | 44.87% | 53.93% | 58.60% | 64.74% | 65.78% | Upgrade
|
| Operating Margin | -19.92% | -73.43% | -163.23% | -286.78% | -687.36% | Upgrade
|
| Profit Margin | -19.74% | -64.29% | -154.16% | -253.30% | -463.06% | Upgrade
|
| Free Cash Flow Margin | - | -54.14% | -105.06% | -199.09% | -698.57% | Upgrade
|
| EBITDA | -83.14 | -229.36 | -355.76 | -428.76 | -376.31 | Upgrade
|
| EBITDA Margin | -10.34% | -54.96% | -144.40% | -269.74% | - | Upgrade
|
| D&A For EBITDA | 77.07 | 77.07 | 46.39 | 27.1 | 9.62 | Upgrade
|
| EBIT | -160.2 | -306.43 | -402.15 | -455.86 | -385.93 | Upgrade
|
| EBIT Margin | -19.92% | -73.43% | -163.23% | -286.78% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.